Table 4 Amplification status assessed by CGH of MDM2, HMGA2, CDK4, JUN, and MAP3K5 in the primary tumor and the four recurrences of case 74
MDM2 | HMGA2 | CDK4 | JUN | MAP3K5 | |
|---|---|---|---|---|---|
Primary tumor: WDLPS | Amplified | Gained | Amplified | Not amplified | Not amplified |
1999 | Log R=3.01 | Log R=1.04 | Log R=3.01 | ||
First recurrence: DDLPS | Amplified | Not gained | Amplified | Amplified | Not amplified |
2008 | Log R=1.72 | Log R=1.25 | Log R=1.83 | ||
Second recurrence: DDLPS | Amplified | Gained | Amplified | Amplified | Not amplified |
2009 | Log R=4.41 | Log R=0.73 | Log R=3.22 | Log R=4.22 | |
Third recurrence: DDLPS | Amplified | Not gained | Gained | Amplified | Not amplified |
2011 | Log R=2.03 | Log R=0.49 | Log R=2.03 | ||
Fourth recurrence: DDLPS | Amplified | Amplified | Amplified | Amplified | Amplified |
2014 | Log R=3.14 | Log R=2.0 | Log R=2.39 | Log R=1.98 | Log R=1.20 |
